Human Anti-TNFRSF10B Recombinant Antibody (TAB-203) (CAT#: TAB-203)
This product is a recombinant Human antibody that recognizes DR5. The antibody was purified by affinity chromatography.
Specific Inquiry
ELISA
Figure 1 Anti-Human DR5 Recombinant Antibody (TAB-203) in ELISA
ELISA analysis of TAB-203 was performed by coating with DR5/TRAIL R2 Protein, Human, Recombinant (His Tag).
The secondary antibody: HRP-Anti-Human IgG (H+L)
WB
Figure 2 Anti-Human DR5 Recombinant Antibody (TAB-203) in WB
Western blot analysis of TAB-203 was performed with DR5/TRAIL R2 Protein, Human, Recombinant (His Tag).
TAB-203 incubation concentration: 2ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)
Lane 1: Reducing Antigen (0.1μg)
Lane 2: Reducing Antigen (0.3μg)
Lane 3: Reducing Antigen (0.6μg)
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Derivation
- Human
- Type
- Human IgG1, κ
- Species Reactivity
- Human
- Applications
- Suitable for use in Neut, ELISA, IF, IP, FuncS, FC, ICC and most other immunological methods.
- MW
- 145.65 kDa
- Related Disease
- Non-small cell lung cancers (NSCLC)
Product Property
- Purity
- >95% as determined by SDS-PAGE
- Buffer
- PBS
- Preservative
- No preservatives
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- DR5; CD262; KILLER; TRICK2; TRICKB; ZTNFR9; TRAILR2; TRICK2A; TRICK2B; TRAIL-R2; KILLER/DR5
- Gene ID
- 8795
- UniProt ID
- O14763
Related Resources
Wang, Liqin, et al. "cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis." Nature Cancer 3.11 (2022): 1284-1299.
This study investigates the effectiveness of combining cFLIP suppression and DR5 activation to target and eliminate senescent cancer cells. Utilizing CRISPR/Cas9-based genetic screens, researchers identified that senescent cells, which are resistant to apoptosis due to high cFLIP expression, can be sensitized to death by activating DR5 with an agonistic antibody. The study demonstrates that this combination treatment, enhanced by BRD2 inhibition, effectively kills senescent cells and induces a bystander effect, leading to the death of adjacent non-senescent cells in various cancer models.
Creative Biolabs significantly contributed to this research by supplying critical reagents. The agonistic antibody targeting DR5 (Cat#: TAB-203) and the BRD2 inhibitor provided by Creative Biolabs were instrumental in the study. These reagents enabled the researchers to validate the therapeutic strategy, demonstrating the potential of combining pro-senescence therapy with DR5 activation in cancer treatment.
More Infomation
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "TNFRSF10B"
Select a product category from the dropdown menu below to view related products.
Please select product type
Single-domain Antibody
Human Antibody
Rat Antibody
Recombinant Antibody
Humanized Antibody
Mouse Antibody
Rabbit Monoclonal Antibody
Agonistic Antibody
scFv Fragment Antibody
ADCC Enhanced Antibody
Fab Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NABL-052 | Recombinant Anti-human TNFRSF10B VHH Single Domain Antibody | WB, ELISA, IHC, FC, FuncS | Llama VHH |
| HPAB-0703-YJ-VHH | Camelid Anti-TNFRSF10B Recombinant Single Domain Antibody (HPAB-0703-YJ-VHH) | ELISA, Apop | Camelid VHH |
| HPAB-0704-YJ-VHH | Camelid Anti-TNFRSF10B Recombinant Single Domain Antibody (HPAB-0704-YJ-VHH) | ELISA | Camelid VHH |
Customer Reviews and Q&As
Customer Review
Q&As
-
Great for TNFRSF10B Research
The Anti-TNFRSF10B Recombinant Antibody has been excellent for our TNFRSF10B studies. Its quality is top-notch, providing clear and reliable results. This product has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time. -
Effective and Dependable
We incorporated this antibody into our TNFRSF10B protocols, and it has been a great asset. The consistency and reliability are impressive, allowing for accurate and reproducible results. The reliable performance has made it an invaluable tool in our lab. -
Consistent High-Quality Results
This antibody has proven to be consistent and high-quality in our TNFRSF10B procedures. The reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The consistent performance has greatly enhanced our data quality.
Cite This Product
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-203, RRID: AB_3111871)
Copy citation
Popular products with customers
Application: WB, ELISA, IP, FC, FuncS, Neut, IF
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: FuncS, IF, Neut, ELISA, FC, IP, IHC
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: FuncS, IF, Neut, ELISA, FC, IP, IHC
Application: FC, IB, Block, Inhib, FuncS, ELISA, FACS, IP, IF
Application: WB, IHC, ELISA, FC
Application: ELISA, IHC, FC, IP, IF, FuncS
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
